London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Investment in medical device technology and R&D have increased the competition among the manufacturers. Whereas manufacturers are focusing on offering advanced features to extracorporeal shock wave lithotripsy at affordable prices to gain a competitive edge in the market. The key players operating in the market are Boston Scientific Corporation, C.R. Bard Inc., Lumenis LTD, GE Healthcare and Siemens AG.
Rising incidence of kidney stones and ureter stones are expected to boost the extracorporeal shock wave lithotripsy market growth. Extracorporeal shock wave lithotripsy is a non-invasive treatment for kidney stone and biliary calculi, using an acoustic pulse and are also used for salivary stones and pancreatic stones. The lithotripter supplies a high intensity acoustic pulse to crush the stone causing minimal collateral damage to the normal tissue and the shock waves break the stones into smaller portion. Extracorporeal shock wave lithotripsy are widely used by the physician globally due to its important characteristic such as non-invasiveness, recovery time, reduced pain and reduced hospital stay. Extracorporeal shock wave lithotripsy success rate is high for patients with smaller stones such as less than 1 centimeter. Also, rise in prevalence of obesity and increasing diabetic patient population also favors growth of the extracorporeal shock wave lithotripsy market.Rampant development of healthcare infrastructure in emerging economies and growing awareness about the availability of technically developed equipment to carry out the procedures favors growth of the market. After extracorporeal shock wave lithotripsy treatment, patient can resume daily activities within one to two days. According to the National Health and Nutrition Examination Survey held in 2012, prevalence of kidney stone was found to be higher in women than in males.Extracorporeal shock wave lithotripsy market is being fuelled by rise in incidence of kidney stones. Extracorporeal shock wave lithotripsy is a valuable tool for eradication of stones from kidney, ureter, gallbladder, salivary gland, or salivary duct. Extracorporeal shock wave lithotripsy is used to find the stone and break it down into smaller fragments. Extracorporeal shock wave lithotripsy generates shockwaves, which are then focused onto the stone present in body with negligible diversion of energy that favors minimal damage to tissue. Extracorporeal shock wave lithotripsy is also most effective in treatment of non-obstructing renal calculi. Whereas the composition and density of stone decides the rate of shockwaves to be generated. Most populated and urbanized regions such as North America, Asia-pacific and European region in the world that uses the advanced devices for treatment purpose shows the largest extracorporeal shock wave lithotripsy market. Europe also favors the growth of market due to increased government investment. The high growth in India and China can be attributed to government and venture capital investments in the field of extracorporeal shock wave lithotripsy to develop the market. Increase in incidence of kidney stone disease in the U.S. also favors the market of extracorporeal shock wave lithotripsy. Investment in medical device technology and R&D have increased the competition among the manufacturers. Whereas manufacturers are focusing on offering advanced features to extracorporeal s
They have sales for research purposes.
I think you are correct the underlying platform TexRAD is world class. There will be multiple applications for this. Feedback do well we do well.
I'm sure they just have GE as a distributor as well? A huge vote of confidence and then potential for sales, but still no sales yet. Unless I've missed something?
I think it is safe to assume Trevor will keep costs really low. And sales channels we have are: GE healthcare India China US hospital already using Imaging Biometrics Latest hospitals using Feedback PACS software the fact UK hospitals are using Feedback PACS means we will easily get Stone Checker in there as it is PACS compliant.
I hadn't see your post so feedback have first sales. I thought they just had the distributor.
How they market, price and distribute their product offers some clues to the route we may take. Of course we could get first sales before them. That would be great.
I am no expert on software pricing models but here are some thoughts.1 A licensing agreement where cost is recurring over time. 2 A licensing agreement where cost is recurring over usage. Cloud based software lends itself to this. I have no idea if they will choose this route, but it adds to the discussion.
Three of the largest manafacturers of Lithotripters are German. EMS, DMT and STORZ. Could this be the German connection that was mentioned.
http://www.healthcareitnews.com/news/fda-chief-sees-big-things-ai-healthcare At AcademyHealth�s 2018 Health Datapalooza on Thursday, the U.S. Food and Drug Administration offered a vote of confidence for artificial intelligence in healthcare, promising more refined strategies for regulation, touting its tech incubator for AI innovation and announcing a new machine learning partnership with Harvard. "We�re implementing a new approach to the review of artificial intelligence," said FDA Commissioner Scott Gottlieb, MD. As one example, he pointed to the agency's approval earlier this year of a new clinical decision support software that uses AI algorithms to help alert neurovascular specialists of brain deterioration faster than existing technologies. "AI holds enormous promise for the future of medicine, and we�re actively developing a new regulatory framework to promote innovation in this space and support the use of AI-based technologies," said Gottlieb. "So, as we apply our Pre-Cert program � where we focus on a firm�s underlying quality � we�ll account for one of the greatest benefits of machine learning � that it can continue to learn and improve as it is used." Doing so, he said, "may allow a firm to make certain minor changes to its devices without having to make submissions each time." FDA also plans to ensure its regulatory framework and software validation tools are "sufficiently flexible to keep pace with the unique attributes of this rapidly advancing field," said Gottlieb. That said, the agency still needs to "establish appropriate guardrails for patients," he emphasized. "And even as we cross-new frontiers in innovation, we must make sure that these novel technologies can deliver benefits to patients by meeting our standards for safety and effectiveness. The technology won�t be scaled or reimbursed without that level of confidence that it protects and promotes patients." Gottlieb said the agency is fully expecting to see an ever-increasing number of AI-powered healthcare tools submitted for approval in the years to come, from imaging devices to technology derived from other industries such as finance "that are already widely using AI platforms for fraud detection." FDA's regulatory approach will "focus on the ways in which real-world data flows," he said. "This includes structured and unstructured data from pathology slides, electronic medical records, wearable devices, and insurance claims data. We want to better understand, and unlock ways, that this data can be used to inform development and validation of AI devices." Whether tools that can scan digital biomarkers for early diagnosis, or leverage EHRs to enable clinical trials at the point of care � or even technology that someday "might even be taught to explain itself to clinicians � Gott
Lithotripters can cost from $100,000 to $200,000 - so easier to just sell this software as part of a lithotripsy equipment,
and what about the training, Urologists will need to be trained on interpreting the software surely?
feedback has sales, this company will also have sales. Its just piggy backing the contacts from there so hope we get some fast sales growth.
upfront cost of purchasing the StoneChecker software so that it can accessed locally an unlimited number of times is expected to be �15,000 with annual recurring revenues based on software maintenance and upgrades, which may include improvements to the TexRAD algorithm based on additional patient data. The intention is to charge a maintenance fee of between �1,500 and �2,000 per year depending on the updates offered. If no additional updates are offered then the maintenance fee may be lowered. Okay so to hit �1million revenue they need to sell 77 software packs. 77 * �15,000. Where can they do this? US, UK, China, Germany , India. Problem is not everyones going to be willing to fork out �15,000 and a lot of urology clinics tend to be private clinics. To elabroate Urology clinics tend to be small and independent, I think they might some sales very quickly - like maybe 10 just from existing contacts and networks but 77 is a big target. Of course the surprising factor could be a NHS deal or private Urology practice deals. How many Urology clincs in NHS UK? Difficult to get exact number if hospital in UK as managed under Trusts, There are 168 trusts. Id knock 30 off just for dirty calculation figure, knock another 30 off as never approached by the sales team here. Pure fag packet calc. so 100 hospitals - so maybe FBDU can pick up a mill here The good thing is there will be recurring revenue from updates and maintenance. It looks like the bigger opportunity will come from direct selling with the Lithotripter manufacturers,
One market leader in the manufacture and sale of lithotripsy solutions has expressed a high level of interest in the StoneChecker product subject to due diligence when the commercial product is available following completion of the patient studies.
I think those are good points you make. The company seem to be doing deals with distributors, and I think they mentioned recently this would be one of the approaches going forward. We have a distributor in Korea and I expect we will have more in other regions. In the States I assume the approach may be different as alluded to in the presentation. Cash is a worry but sales look likely in the near future.
apologies for wrong link in last post -alba, i'm not invested in them and never will....dragged it over by mistake, sorry
later on.
Okay, before you all starts yelling at me....I am a sharholder and believe in this story. I would just make a few observations: 1. Shouldnt the Biz Development team have been built up already for the CE Mark side of the business. We have been free to sell in Europe for a while now and no sales. Not clear what strategy we are following on this side? 2. We have 387K of cash and a burn last year of 258K....guess the burn will be faster now we have the costs of the US company too?. For whom I have not been able to find any financials online. So how long do we have cash for 6 months, 9 months? Are we going to get sales prior to cash running out?? 3. Would be quite disappointing if we get FDA approval and then silence on the sales. Surely this has been underway simultanesouly. From the RNS seems not. Comments from anyone???
Are you in feedback, it looks good over there. If i remember correctly it didn't really move on fda approval. First sales should do the trick here. Quite surprised about the sales potential in Korea. I will be adding more over the coming months.
I agree, any hint/leak of GE involvement could set these shares alight. Slight tick up today could indicate something afoot?
Just needs same annoucment as Feedback and this will go flying. GE in India must be the India deal they are looking at , these guys are using their feedback and Imaging Biometrics contacts
I don’t think this will rise will be sustained cos there is too much of a wait I think. But that’s not to say the fundamentals are not sound. I’m still in just waiting to see when is a good time to add more. But hey I guess no One ever gets that right do we now ?